 |
|  |
Jul-10-19 | Resumed |
Credit Suisse |
Neutral |
|
|
Mar-27-19 | Upgrade |
Morgan Stanley |
Underweight → Equal-Weight |
|
|
Feb-25-19 | Upgrade |
H.C. Wainwright |
Sell → Neutral |
$14 |
|
Jan-24-19 | Upgrade |
JP Morgan |
Underweight → Neutral |
|
|
Nov-07-18 | Downgrade |
JP Morgan |
Neutral → Underweight |
|
|
Nov-07-18 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
Jul-23-18 | Initiated |
H.C. Wainwright |
Sell |
$12.50 |
|
May-09-18 | Downgrade |
Morgan Stanley |
Equal-Weight → Underweight |
|
|
Jan-05-18 | Downgrade |
BofA/Merrill |
Buy → Underperform |
|
|
Dec-06-17 | Downgrade |
Mizuho |
Buy → Neutral |
$16 |
|
Jul-21-17 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
May-03-17 | Initiated |
Wells Fargo |
Outperform |
|
|
Apr-07-17 | Reiterated |
Mizuho |
Buy |
$21 → $22 |
|
Feb-22-17 | Reiterated |
Barclays |
Equal Weight |
$13 → $16 |
|
Nov-04-16 | Reiterated |
Mizuho |
Buy |
$19 → $20 |
|
Oct-24-16 | Reiterated |
Wedbush |
Neutral |
$10 → $13 |
|
Oct-10-16 | Reiterated |
Mizuho |
Buy |
$24 → $19 |
|
Sep-27-16 | Reiterated |
WallachBeth |
Hold |
$15 → $17 |
|
Jul-15-16 | Reiterated |
Mizuho |
Buy |
$16 → $24 |
|
May-10-16 | Reiterated |
Mizuho |
Buy |
$15 → $16 |
|
|
 |
Dec-13-19 08:39AM | Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks |
Dec-10-19 09:15AM | Some Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Are Down 21% Simply Wall St. |
08:33AM | Turning Point (TPTX) Catches Eye: Stock Jumps 6.1% Zacks |
Dec-09-19 10:20AM | Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks |
Dec-03-19 08:51AM | Top Ranked Momentum Stocks to Buy for December 3rd Zacks |
Nov-29-19 09:39AM | Catalyst Focuses on Firdapse Label Expansion Amid Competition Zacks |
Nov-27-19 08:21AM | The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics Zacks |
Nov-26-19 09:36AM | 5 Best-Performing, Top-Ranked Growth Stocks of November Zacks |
Nov-22-19 09:48AM | The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical Zacks |
Nov-21-19 12:15PM | Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD Zacks |
Nov-19-19 09:13AM | Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks |
Nov-11-19 09:21AM | FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks |
Nov-08-19 09:24AM | Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue? Zacks |
08:00AM | Pharma Sector Tops in October: Best ETFs & Stocks Zacks |
Nov-06-19 02:23PM | Edited Transcript of IRWD earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents |
10:36AM | Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks |
10:20AM | Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock Zacks |
Nov-05-19 04:05PM | Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference Business Wire |
Nov-01-19 10:52AM | Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks |
Oct-31-19 09:05AM | Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates Zacks +6.47% |
07:00AM | Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance Business Wire |
Oct-30-19 08:17AM | Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals |
Oct-28-19 10:23AM | Hedge Funds Ditched Ironwood Pharmaceuticals, Inc. (IRWD) At The Right Time Insider Monkey |
08:00AM | Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting Business Wire |
Oct-24-19 10:32AM | Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth Zacks |
Oct-17-19 04:05PM | Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call Business Wire |
Oct-11-19 08:14AM | Are Investors Undervaluing Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) By 46%? Simply Wall St. |
Sep-19-19 02:31PM | Ironwood Amends Linzess Agreement with AstraZeneca in China Zacks |
Sep-18-19 07:39AM | The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts Benzinga |
02:00AM | Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China Business Wire |
Sep-13-19 11:08AM | Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment Zacks |
Sep-10-19 03:18PM | Investors Can Find Big Returns with this First Profit Screen Zacks +6.08% |
Sep-04-19 10:31AM | Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study Zacks |
Aug-30-19 06:14PM | 5 Health Care Stocks in Gurus' Portfolios GuruFocus.com |
Aug-28-19 04:05PM | Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire |
Aug-27-19 08:05AM | Here's Why Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Afford Some Debt Simply Wall St. |
Aug-13-19 04:50PM | Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment Business Wire |
07:30AM | Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire |
07:30AM | Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire |
Aug-08-19 07:30AM | Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering Business Wire |
Aug-06-19 04:05PM | Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes Business Wire |
Aug-03-19 04:45AM | Edited Transcript of IRWD earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents |
Jul-31-19 10:58AM | Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks |
06:00AM | Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know Motley Fool |
04:24AM | Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript Motley Fool |
Jul-30-19 08:45PM | Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates Zacks |
04:01PM | Ironwood Pharmaceuticals Reports Second Quarter 2019 Results Business Wire |
Jul-23-19 10:32AM | Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks |
Jul-19-19 12:15PM | Should You Be Concerned About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Historical Volatility? Simply Wall St. |
Jul-18-19 04:05PM | Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call Business Wire |
Jun-21-19 06:09AM | 100 Summer lands WeWork ahead of tower's possible sale American City Business Journals |
Jun-20-19 07:09PM | Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey |
09:40AM | Company News For Jun 20, 2019 Zacks |
Jun-19-19 05:21PM | Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients Zacks |
10:22AM | Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective Benzinga |
Jun-18-19 04:05PM | Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire +8.08% |
Jun-13-19 05:14PM | Cambridges Ironwood Pharma moving HQ to downtown Boston American City Business Journals |
04:30PM | Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston Business Wire |
Jun-05-19 09:50AM | Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks |
Jun-03-19 08:30AM | Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D Business Wire |
Jun-01-19 09:32AM | Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report? Zacks |
May-24-19 08:00PM | Sarissa Capital Is Drawn to Ironwood Pharmaceuticals Barrons.com |
May-17-19 01:58PM | Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today Motley Fool +13.74% |
May-16-19 04:07PM | 6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com |
04:55AM | Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents |
May-09-19 08:00AM | Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019 Business Wire |
May-08-19 01:25PM | Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%? Simply Wall St. |
May-07-19 04:05PM | Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference Business Wire |
May-03-19 08:36AM | Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks |
May-02-19 08:24PM | Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript Motley Fool -12.82% |
12:13PM | Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ? Insider Monkey |
09:35AM | Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates Zacks |
08:24AM | Ironwood: 1Q Earnings Snapshot Associated Press |
07:00AM | Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance Business Wire |
Apr-25-19 10:34AM | Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks |
Apr-18-19 04:05PM | Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call Business Wire |
Apr-16-19 04:02PM | Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020 Business Wire |
Apr-05-19 10:34AM | Will Ironwood Suffer From Dependence on Linzess' Progress? Zacks |
Apr-02-19 06:23AM | As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start' American City Business Journals |
Apr-01-19 04:02PM | Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company Business Wire |
Mar-27-19 02:56PM | Ironwood's new CEO has big plans for Linzess, but is mum on R&D American City Business Journals |
Mar-16-19 10:07AM | Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Simply Wall St. |
Mar-15-19 09:30AM | Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report? Zacks |
Mar-14-19 04:54PM | Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement Business Wire |
Mar-07-19 04:05PM | Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Business Wire |
Mar-04-19 04:05PM | Ironwood Pharmaceuticals to Present at Cowen Health Care Conference Business Wire |
Feb-28-19 08:30AM | Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
Feb-26-19 09:00AM | Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering Business Wire |
Feb-21-19 04:05PM | Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference Business Wire |
Feb-14-19 10:02AM | Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks -5.63% |
07:27AM | Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT Thomson Reuters StreetEvents |
Feb-13-19 05:17PM | Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool +11.66% |
03:29PM | Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript Motley Fool |
08:50AM | Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates Zacks |
07:52AM | Ironwood: 4Q Earnings Snapshot Associated Press |
07:00AM | Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Business Wire |
Feb-10-19 05:37PM | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga |
Feb-06-19 10:30AM | Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline Zacks |
Jan-29-19 10:43AM | Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid Zacks |
Jan-28-19 05:00PM | Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Business Wire |
|
|
|
 |
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
MacDonald Kelly | Chief Accounting Officer | Nov 08 | Sale | 11.00 | 987 | 10,857 | 78,337 | Nov 12 06:26 PM | Consylman Gina | SVP, CFO & Treasurer | Nov 08 | Sale | 11.00 | 1,510 | 16,610 | 174,138 | Nov 12 06:23 PM | MCCOURT Thomas A | President | Aug 30 | Option Exercise | 4.88 | 220,000 | 1,073,600 | 329,739 | Sep 04 04:42 PM | MCCOURT Thomas A | President | Aug 30 | Sale | 9.24 | 220,000 | 2,032,800 | 109,739 | Sep 04 04:42 PM | Consylman Gina | SVP, CFO & Treasurer | Aug 16 | Sale | 9.04 | 212 | 1,916 | 175,648 | Aug 20 05:37 PM | Gilbert Halley E | Chief Admin Officer & SVP | Jul 26 | Option Exercise | 4.88 | 20,000 | 97,600 | 260,169 | Jul 30 04:48 PM | Gilbert Halley E | Chief Admin Officer & SVP | Jul 26 | Sale | 10.00 | 20,000 | 200,000 | 240,169 | Jul 30 04:48 PM | OLANOFF LAWRENCE S | Director | Jun 05 | Sale | 11.25 | 2,000 | 22,500 | 58,259 | Jun 07 04:06 PM | McHugh Julie | Director | Jun 05 | Sale | 11.26 | 1,500 | 16,890 | 109,337 | Jun 07 04:05 PM | MCCOURT Thomas A | President | May 10 | Sale | 10.53 | 4,055 | 42,699 | 107,239 | May 14 04:13 PM | Gilbert Halley E | Chief Admin Officer & SVP | May 10 | Sale | 10.53 | 4,055 | 42,699 | 238,240 | May 14 04:12 PM | Currie Mark G | Director | May 10 | Sale | 10.53 | 4,055 | 42,699 | 528,903 | May 14 04:10 PM | Consylman Gina | SVP, CFO & Treasurer | May 10 | Sale | 10.53 | 4,055 | 42,699 | 175,860 | May 14 04:08 PM | Currie Mark G | Chief Scientific Officer | Mar 08 | Sale | 13.15 | 49,500 | 650,925 | 528,480 | Mar 08 05:51 PM | Currie Mark G | Chief Scientific Officer | Mar 07 | Sale | 13.29 | 225,500 | 2,996,895 | 577,980 | Mar 08 05:51 PM | McHugh Julie | Director | Mar 05 | Sale | 14.38 | 1,500 | 21,570 | 88,131 | Mar 06 04:07 PM | OLANOFF LAWRENCE S | Director | Mar 05 | Sale | 14.41 | 2,000 | 28,820 | 37,553 | Mar 06 04:06 PM | MCCOURT Thomas A | Chief Commercial Officer | Feb 21 | Sale | 14.32 | 41 | 587 | 83,309 | Feb 22 04:53 PM | Gilbert Halley E | Chief Legal Officer | Feb 21 | Sale | 14.32 | 85 | 1,217 | 225,130 | Feb 22 04:51 PM | Currie Mark G | Chief Scientific Officer | Feb 21 | Sale | 14.32 | 13 | 186 | 803,480 | Feb 22 04:49 PM | Consylman Gina | Chief Financial Officer | Feb 21 | Sale | 14.32 | 46 | 659 | 163,184 | Feb 22 04:47 PM | MCCOURT Thomas A | Chief Commercial Officer | Feb 20 | Sale | 14.31 | 4,800 | 68,688 | 83,350 | Feb 22 04:53 PM | Gilbert Halley E | Chief Legal Officer | Feb 20 | Sale | 14.31 | 10,157 | 145,347 | 225,215 | Feb 22 04:51 PM | Currie Mark G | Chief Scientific Officer | Feb 20 | Sale | 14.31 | 1,631 | 23,340 | 803,493 | Feb 22 04:49 PM | Consylman Gina | Chief Financial Officer | Feb 20 | Sale | 14.31 | 5,631 | 80,580 | 163,230 | Feb 22 04:47 PM | Gilbert Halley E | Chief Legal Officer | Jan 30 | Option Exercise | 4.89 | 20,449 | 99,996 | 235,372 | Jan 31 05:35 PM | Hecht Peter M | Chief Executive Officer | Jan 25 | Option Exercise | 4.89 | 50,000 | 244,500 | 4,726,468 | Jan 25 06:24 PM | Hecht Peter M | Chief Executive Officer | Jan 25 | Sale | 12.23 | 29,551 | 361,409 | 4,696,917 | Jan 25 06:24 PM | Hecht Peter M | Chief Executive Officer | Jan 24 | Option Exercise | 4.89 | 30,000 | 146,700 | 4,726,917 | Jan 25 06:24 PM | Hecht Peter M | Chief Executive Officer | Jan 24 | Sale | 12.70 | 30,000 | 381,000 | 4,696,917 | Jan 25 06:24 PM | Hecht Peter M | Chief Executive Officer | Jan 23 | Option Exercise | 4.89 | 30,000 | 146,700 | 4,726,917 | Jan 25 06:24 PM | Hecht Peter M | Chief Executive Officer | Jan 23 | Sale | 12.66 | 30,000 | 379,800 | 4,696,917 | Jan 25 06:24 PM |
|
 |
|
 |
|